Angiodynamics, Inc. (ANGO)
NASDAQ:ANGO
Top Page
AngioDynamics
(NASDAQ:ANGO)
Select Model
Select Model
Rating:58Neutral
Price Target:
$10.50
▼(-3.85% Downside)
Action:ReiteratedDate:04/03/26
The score is driven primarily by solid financial resilience (debt-free balance sheet, stable gross margins) but restrained by ongoing operating losses and inconsistent free cash flow. The latest earnings call is a meaningful positive due to raised FY2026 guidance and strong Med Tech platform momentum, while technicals are mixed-to-weak with the stock trading below major moving averages. Valuation is less supportive given negative earnings and no dividend yield provided.
Positive Factors
Debt-free balance sheet
Zero meaningful debt and positive equity give AngioDynamics durable financial flexibility, lowering refinancing risk and enabling funding for R&D, commercial expansion, and a planned inventory build. This structural strength supports multi-quarter investments despite uneven profitability.
Negative Factors
Persistent operating and net losses
Ongoing operating and net losses constrain the company's ability to consistently reinvest and compound returns; negative margins reduce retained earnings and limit ROE improvement, making long-term value creation contingent on sustained margin recovery from product mix and cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero meaningful debt and positive equity give AngioDynamics durable financial flexibility, lowering refinancing risk and enabling funding for R&D, commercial expansion, and a planned inventory build. This structural strength supports multi-quarter investments despite uneven profitability.
Read all positive factors
AngioDynamics (ANGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$416.91M
Dividend YieldN/A
Average Volume (3M)426.73K
Price to Earnings (P/E)―
Beta (1Y)0.16
Revenue Growth2.73%
EPS Growth87.03%
CountryUS
Employees748
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.02
Shares Outstanding41,318,916
10 Day Avg. Volume628,409
30 Day Avg. Volume426,726
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.28
Price to Sales (P/S)1.43
P/FCF Ratio-28.65
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue1.17
Enterprise Value/Gross Profit2.19
Enterprise Value/Ebitda-94.42
Forecast
1Y Price Target
$16.00Price Target Upside46.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$314.12M
AngioDynamics Business Overview & Revenue Model
Company Description
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surg...
How the Company Makes Money
AngioDynamics makes money primarily by selling medical devices and related disposable products to healthcare providers (e.g., hospitals and clinics) and, depending on the product and geography, through direct sales forces and/or third-party distri...
AngioDynamics Earnings Call Summary
Earnings Call Date:Apr 02, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Jul 21, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum driven by Med Tech platforms (Auryon, AlphaVac/AngioVac, NanoKnife), multiple product- and regulatory-level achievements, and upward revisions to revenue and adjusted EBITDA guidance — all positive indicators. Notable headwinds include a 110-bp gross margin decline tied to tariffs and manufacturing transition, an expected $4M–$6M tariff hit for FY2026, a planned $3M–$5M inventory build that may slightly depress FY cash flow, and continued adjusted net losses. On balance, the operational wins, raised guidance, and sustained product adoption outweigh the identified near-term margin and cash pressures.Positive Updates
Quarterly Revenue Growth and Raised Full-Year Guidance
Total revenue increased 8.9% YoY to $78.4M in Q3. Management raised FY2026 net sales guidance to $313.5M-$315.5M (up from $312M-$314M), implying 7.1%–7.8% growth vs FY2025. Adjusted EBITDA guidance was raised to $10M-$12M (from $8M-$10M).
Negative Updates
Gross Margin Pressure from Tariffs, Inflation and Manufacturing Transition
Gross margin fell to 52.9% in Q3, a decline of 110 basis points YoY. Management cites tariffs, inflation and costs tied to a manufacturing transition as primary drivers of the margin compression.
Read all updates
Q3-2026 Updates
Positive
Negative
Quarterly Revenue Growth and Raised Full-Year Guidance
Total revenue increased 8.9% YoY to $78.4M in Q3. Management raised FY2026 net sales guidance to $313.5M-$315.5M (up from $312M-$314M), implying 7.1%–7.8% growth vs FY2025. Adjusted EBITDA guidance was raised to $10M-$12M (from $8M-$10M).
Read all positive updates
Company Guidance
AngioDynamics raised FY2026 guidance, now expecting net sales of $313.5–315.5M (up from $312–314M), implying 7.1%–7.8% growth versus FY2025 revenue of $292.7M; segment guidance calls for Med Tech growth of 15%–17% and Med Device roughly 1%. Management reiterated gross margin of 53.5%–55.5% (inclusive of an expected $4–6M of tariffs for the year; Q3 tariff expense was $1.3M and Q3 gross margin was 52.9%, down 110 bps YoY) and raised adjusted EBITDA to $10–12M (from $8–10M), while expecting an adjusted loss per share of $0.30–$0.23 (improved from prior $0.33–$0.23); Q3 adjusted EBITDA was $1.8M and Q3 adjusted net loss was $3.0M (–$0.07/share) versus $3.1M (–$0.08) a year ago. The company noted adjusted EBITDA will be lower in H2 due to planned clinical investments, targets R&D at ~10% of sales, ended Q3 with $37.8M cash (vs. $41.6M at 11/30/25) after using $3.1M in the quarter, and expects strong Q4 cash generation but plans a $3–5M inventory build in the back half that could make FY2026 cash flow slightly negative; balance sheet remains debt-free.AngioDynamics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 313.73M | 292.50M | 303.91M | 338.75M | 316.22M | 291.01M |
| Gross Profit | 167.69M | 157.71M | 154.70M | 174.25M | 165.73M | 156.79M |
| EBITDA | -3.89M | 1.74M | -6.13M | 12.19M | 11.13M | -9.28M |
| Net Income | -31.39M | -33.99M | -184.35M | -52.44M | -26.55M | -31.55M |
Balance Sheet | ||||||
| Total Assets | 260.68M | 280.14M | 317.67M | 532.64M | 552.75M | 561.44M |
| Cash, Cash Equivalents and Short-Term Investments | 37.81M | 55.89M | 76.06M | 44.62M | 28.82M | 48.16M |
| Total Debt | 0.00 | 0.00 | 4.73M | 64.58M | 33.78M | 20.00M |
| Total Liabilities | 87.32M | 97.17M | 112.08M | 154.34M | 128.26M | 121.98M |
| Stockholders Equity | 173.36M | 182.97M | 205.59M | 378.30M | 424.49M | 439.46M |
Cash Flow | ||||||
| Free Cash Flow | 1.50M | -14.59M | -33.93M | -4.27M | -11.49M | 18.91M |
| Operating Cash Flow | 4.45M | -10.13M | -28.16M | 78.00K | -7.19M | 24.09M |
| Investing Cash Flow | -7.30M | -10.18M | 123.72M | -9.75M | -19.31M | -13.71M |
| Financing Cash Flow | -5.10M | -255.00K | -64.25M | 25.42M | 7.68M | -16.99M |
AngioDynamics Technical Analysis
Negative
10.92
Price Trends
10.81
Negative
11.48
Negative
10.90
Negative
Market Momentum
-0.20
Positive
42.77
Neutral
23.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANGO, the sentiment is Negative. The current price of 10.92 is above the 20-day moving average (MA) of 10.66, above the 50-day MA of 10.81, and above the 200-day MA of 10.90, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 42.77 is Neutral, neither overbought nor oversold. The STOCH value of 23.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANGO.
AngioDynamics Risk Analysis
AngioDynamics disclosed 34 risk factors in its most recent earnings report. AngioDynamics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AngioDynamics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $194.47M | 27.96 | 11.91% | ― | 6.23% | 283.88% | |
58 Neutral | $416.91M | ― | -17.65% | ― | 2.73% | 87.03% | |
56 Neutral | $206.58M | 16.41 | 9.56% | 2.15% | -12.35% | -17.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $211.53M | -2.25 | -18.58% | ― | -43.95% | -620.21% | |
47 Neutral | $189.64M | -9.67 | -191.60% | ― | 19.61% | -3.42% | |
46 Neutral | $155.56M | -5.36 | -178.57% | ― | 30.55% | -340.19% |
* Healthcare Sector Average
ANGO
AngioDynamics
10.09
0.80
8.61%
INFU
InfuSystem Holdings
9.62
4.64
93.17%
OSUR
Orasure Technologies
3.06
0.13
4.44%
STXS
Stereotaxis
1.95
0.29
17.47%
UTMD
Utah Medical Products
64.86
12.91
24.84%
SMTI
Sanara MedTech
16.97
-12.08
-41.58%
AngioDynamics Corporate Events
Business Operations and StrategyFinancial Disclosures
AngioDynamics Posts Strong Q3 Results, Raises 2026 Guidance
Positive
Apr 2, 2026
On April 2, 2026, AngioDynamics reported fiscal third-quarter 2026 results for the period ended February 28, 2026, posting pro forma net sales of $78.4 million, up 8.9% year on year, driven by 19% Med Tech growth to $37.3 million while Med Device ...
Business Operations and StrategyExecutive/Board Changes
AngioDynamics announces CEO transition and leadership retention plan
Neutral
Feb 3, 2026
On February 3, 2026, AngioDynamics entered into a Transition and Retirement Agreement with President and CEO James C. Clemmer, confirming that he will remain in his role until a successor is appointed or until November 30, 2026, with the potential...
Business Operations and Strategy
AngioDynamics Highlights Growth Strategy at J.P. Morgan Conference
Positive
Jan 14, 2026
On January 14, 2026, President and CEO James Clemmer presented AngioDynamics’ growth strategy and product portfolio at the J.P. Morgan 44th Annual Healthcare Conference, highlighting the company’s transition since 2020 into a more grow...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresLegal ProceedingsRegulatory Filings and Compliance
AngioDynamics posts strong Q2 results, raises 2026 outlook
Positive
Jan 6, 2026
On January 6, 2026, AngioDynamics reported financial results for its fiscal second quarter ended November 30, 2025, highlighted by 8.8% year-on-year pro forma net sales growth to $79.4 million and the fifth consecutive quarter of double-digit grow...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.